MONALISA · MOtorized NAnomachines: fundamentaLs, InnovationS, Applications
Horizon Europe — Marie Skłodowska-Curie Actions
- Duration
- 2024-12-01 → 2028-11-30
- EU contribution
- €4,048,481
- Participants
- 21
- Scheme
- HORIZON-TMA-MSCA-DN
Lines connect the coordinator with its partners.
Project objective
MonaLisa, a pioneering European consortium, is at the forefront of artificial molecular machine research, setting the stage for breakthroughs in chemical synthesis, nanotechnology, medical treatment and smart materials. Building on the foundational work recognised by the 2016 Nobel Prize in Chemistry, MonaLisa aims to make groundbreaking discoveries in the design and functional control of molecular machines that will lead to first demonstrations with practical relevance. At the heart of MonaLisa is an innovative training programme. Fifteen doctoral candidates will receive comprehensive mentoring and training to become future leaders in the field. The programme is designed to foster not only academic excellence but also entrepreneurial skills, enabling these professionals to translate scientific breakthroughs into innovations and support evidence-based decision-making. The strength of MonaLisa lies in its joint vision and collaborative framework, bringing together top scientists, including four Nobel laureates, prestigious institutions and a wide range of industry partners. The non-academic support ranges from dynamic SMEs to large global players, supported by leading organisations that act as multipliers, fostering new programmes and partnerships. Looking to the future, MonaLisa is committed to developing sustainable, educational structures that integrate the non-academic sector to cultivate skills essential for the academic and non-academic workplaces of the 21st century. This initiative will increase collaboration, research intensity and innovation capacity within the European chemistry ecosystem. In doing so, MonaLisa is poised to secure Europe's leadership in science and technology, driving economic growth and societal benefits.
Original text from CORDIS.
Participants
- CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS · ParisCoordinatorFrance
- ALMA MATER STUDIORUM - UNIVERSITA DI BOLOGNA · BolognaItaly
- Clariant AG · TarragonaSwitzerland
- European Chemical Society (EuChemS) · IxellesBelgium
- Foresight Institute · San FranciscoUnited States
- Merck Millipore Ltd. · CorkIreland
- Orgentis Chemicals GmbHGermany
- Oriensys srl · StrasbourgFrance
- RIJKSUNIVERSITEIT GRONINGEN · GroningenNetherlands
- SOPREMA · STRASBOURGFrance
- SPECIALTY OPERATIONS FRANCE · LYONFrance
- SYENSQO LABORATOIRE DU FUTUR SAS · PESSACFrance
- Springer Nature AG & Co. KGaA · BerlinGermany
- TECHNISCHE UNIVERSITAET DRESDEN · DresdenGermany
- TECHNISCHE UNIVERSITAET MUENCHEN · MuenchenGermany
- The DESCA Foundation · DoverUnited States
- UNIVERSITE DE BORDEAUX · BordeauxFrance
- UNIVERSITE DE LIEGE · LIEGEBelgium
- UNIVERSITE DE STRASBOURG · StrasbourgFrance
- WILEY-VCH VERLAG GMBH & CO KGAA · WeinheimGermany
- XELTIS BV · EINDHOVENNetherlands
Links
Data: CORDIS, © European Union